Crossmark

Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab

Crossref DOI link: https://doi.org/10.1016/j.medcle.2021.06.023

Published Print: 2022-06

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Sánchez-Montalvá, Adrián

Sellarés-Nadal, Júlia

Espinosa-Pereiro, Juan

Fernández-Hidalgo, Nuria

Pérez-Hoyos, Santiago

Salvador, Fernando

Durà, Xavier

Miarons, Marta

Antón, Andrés

Eremiev-Eremiev, Simeón

Sempere-González, Abiu

Monforte-Pallarés, Arnau

Bosch-Nicolau, Pau

Augustin, Salvador

Sampol, Júlia

Guillén-del-Castillo, Alfredo

Almirante, Benito
License Information

Text and Data Mining valid from 2022-06-01

stm-asf valid from 2022-06-01

stm-asf valid from 2022-06-01

stm-asf valid from 2022-06-01

stm-asf valid from 2022-06-01

stm-asf valid from 2022-06-01
More Information

This article is maintained by: Elsevier

Article Title: Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab

Journal Title: Medicina Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.medcle.2021.06.023

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.medcli.2021.06.012

Content Type: article

Copyright: © 2021 Elsevier España, S.L.U. All rights reserved.